Physician profile
Angelo Markatos
NPI 1447279245
$6,480.48
in general payments reported to CMS, 2019-2025
29 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $645 · 2021: $519 · 2022: $835 · 2023: $1,035 · 2024: $1,301 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460 · Education: $23.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.44 |
| Education | $23.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,852.33 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,027.78 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $474.55 | 2021-2025 | |
| Ardelyx, INC. | $430.73 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $327.56 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $285.56 | 2022-2024 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.93 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $235.73 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $165.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $142.85 | 2019-2023 | Injectafer |
| W. L. Gore & Associates, INC. | $142.74 | 2019 | |
| Calliditas Therapeutics US INC. | $131.38 | 2022-2024 | |
| Amgen INC. | $129.21 | 2024-2025 | Tavneos, Krystexxa |
| Lemaitre Vascular, INC. | $128.27 | 2024 | Artegraft Vascular Graft |
| Fresenius USA Marketing, INC. | $114.45 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.67 | 2019-2023 | Jynarque |
| Lilly USA, LLC | $83.61 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $78.54 | 2020-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $76.64 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $65.28 | 2025 | |
| Akebia Therapeutics INC | $53.46 | 2019-2022 | |
| Scpharmaceuticals INC. | $46.25 | 2025 | |
| Ascendis Pharma Endocrinology INC | $35.00 | 2025 | Yorvipath |
| Shire North American Group INC | $29.10 | 2019 | |
| Genzyme Corporation | $23.21 | 2023 | |
| Alexion Pharmaceuticals, INC. | $14.86 | 2020 | |
| Pharmacosmos Therapeutics INC. | $14.51 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.48 | 2023 | Givlaari |
| Corcept Therapeutics | $13.90 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Markatos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.